NuraLogix’s Anura™ Telehealth
Contactless Vitals Monitoring
NuraLogix is a pioneer in the development of Affective Ai™, the intersection between affective computing and artificial intelligence that can recognize, measure, predict, and simulate human affects that take the form of physiological and psychological states. Its DeepAffex™ Affective Ai™ platform can measure over 100 health and wellness parameters using a conventional video camera from any device such as a smartphone, tablet, or laptop and is the world’s most comprehensive contactless blood pressure measurement technology. Leveraging its patented Transdermal Optical Imaging (TOI™) technology, a novel form of Remote Photoplethysmography (rPPG), it assesses facial blood flow patterns to measure physical and mental vital signs as well as provide health risk assessments.
In October 2023, NuraLogix launched Anura™ Telehealth, a solution for integration into healthcare professionals’ telehealth offerings which is powered by DeepAffex™. This enables doctors to receive real-time telemetrics during telehealth sessions. Anura™ Telehealth can integrate with third-party video conference platforms and is compatible with telehealth solutions such as Doxy.me. Additionally, it offers customizable interfaces, templates, and reporting to accommodate different use cases.
Uniquely, Anura™ can assess HbA1c, monitor fasting glucose, and assess the risk of type 2 diabetes, hypertension, and hypertriglyceridemia. Its research models have currently appeared in 10 global peer-reviewed research publications, with three additional publications in progress covering topics of hypertension, multi-year cardiovascular risk, diabetes, and fatty liver disease. Its latest released models have been proven to predict whether a subject’s HbA1c is greater than 5.7% or their Fasting Blood Glucose is greater than 5.5mmol/L to a clinically accurate level. However, in the U.S. some features of DeepAffex™ are for investigational use only.
